Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Neurocrine’s Ingrezza to treat tardive dyskinesia
Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, which is claimed to be the only FDA-approved product to treat adults with TD. FDA approval was based
Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, which is claimed to be the only FDA-approved product to treat adults with TD. FDA approval was based
Emtricitabine / tenofovir disoproxil (Truvada) was approved to prevent sexually transmitted HIV-1 infection in adults who are at high risk of infection, a condition known as pre-exposure prophylaxis (PrEP). Truvada
The global and randomised phase III ALEX study met its primary endpoint, demonstrating that Alecensa as an initial (first-line) treatment has decreased the risk of disease worsening or death
The models will predict therapeutic indications and side effects from several drug information sources The invention of the new machine learning models is likely to pave way for
The company intends to provide data from trial evaluating cardiovascular outcomes with sitagliptin (TECOS), which includes prescribing information of sitagliptin-containing medicines. The TECOS trial, which involved 4,724 patients
HoFH is an inherited disorder, which can result in premature cardiovascular disease due to high levels of LDL cholesterol. Evinacumab is an investigational monoclonal antibody to angiopoietin-like protein
The trial had assessed the efficacy, safety and tolerability of a single administration of two different doses of Botox, including 30 units (30U) or 50 units (50 U),
The study, dubbed OPTIC, assessed the safety and efficacy of once-daily, IV-to-oral omadacycline in comparison to IV-to-oral moxifloxacin in the treatment of CABP in adults. In the clinical trial featuring 774
Imbruvica is an oral and once-daily therapy, which suppresses Bruton's tyrosine kinase (BTK) protein, which is a signaling molecule in the B-cell receptor signaling complex that will spread
Formerly known under the developmental name SD-809, austedo has now become the first deuterated product to get FDA approval and also the second drug approved in HD. Previously